Site News

Added 10 hours ago Drug news

FDA issues a Complete Response Letter to Evolus for DWP 450 a proposed treatment for glabellar lines.

Evolus, Inc.has announced updates related to the regulatory progress of its pending Biologics License Application (“BLA”) for DWP 450 (prabotulinumtoxinA)...

Added 10 hours ago Drug news

Pfizer announces Phase III study of Lyrica for patients with pediatric epilepsy.

Pfizer Inc. announced positive top-line results of a Phase III study examining the use of Lyrica (pregabalin) Oral Solution CV...

Added 10 hours ago Drug news

Phase III SPARTAN study of Erleada shows reduced risk of prostate cancer.- Janssen Pharma.

Janssen Pharmaceutical presented a post-hoc analysis from the Phase III SPARTAN study that showed treatment with Erleada (apalutamide) significantly reduced...

Added 1 day ago Drug news

ENGAGE AF-TIMI 48 trial of Lixiana shows reduced rates of intracranial haemorrhage for patients with atrial fibrillation.- Daiichi Sankyo.

Daiichi Sankyo Europe announced new sub-analysis data from the ENGAGE AF-TIMI 48 trial, which demonstrates that patients with atrial fibrillation...

Added 1 day ago Drug news

FDA approves Aimovig for prevention of migraine.- Novartis + Amgen.

Novartis has announced that the FDA has approved Aimovig (erenumab) for the preventive treatment of migraine in adults. Aimovig is...

Added 2 days ago Drug news

Positive follow up data from Phase III ALEX study of Alecensa shows reduced risk of disease progression or death in ALK positive NSCLC.- Genentech/Roche

Genentech, a member of the Roche Group announced follow-up data from the Phase III ALEX study, showing that as an...

Added 2 days ago Drug news

FDA approves Lucemyra to mitigate opioid withdrawal symptoms.- US WorldMeds

US WorldMeds announced that the FDA approved Lucemyra (lofexidine) for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation...

Added 2 days ago Drug news

Phase III study of Epidiolex in Lennox-Gastaut Syndrome published in NEJM.- GW Pharma.

The second of two phase III studies showing that Epidiolex (cannabinoid) from GW Pharma, cut seizures in patients with the...

Added 2 days ago Drug news

Phase III SYGMA trials of Symbicort Turbohaler for asthma "as needed" are published in NEJM. -AstraZeneca

AstraZeneca announced results from the Phase III SYGMA trials of Symbicort Turbuhaler (budesonide/formoterol) given as an anti-inflammatory reliever ‘as needed’...

Added 2 days ago Drug news

Tecentriq + Avastin + chemotherapy shows survival advantage for first line treatment of NSCLC patients.- Genentech/Roche.

A survival advantage for the Tecentriq and Avastin combination regimen was observed in all pre-specified exploratory patient subgroups analyzed, including...

Search all news articles